RU2018127191A - Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы - Google Patents

Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы Download PDF

Info

Publication number
RU2018127191A
RU2018127191A RU2018127191A RU2018127191A RU2018127191A RU 2018127191 A RU2018127191 A RU 2018127191A RU 2018127191 A RU2018127191 A RU 2018127191A RU 2018127191 A RU2018127191 A RU 2018127191A RU 2018127191 A RU2018127191 A RU 2018127191A
Authority
RU
Russia
Prior art keywords
composite
paragraphs
api
sucralose
hpβcd
Prior art date
Application number
RU2018127191A
Other languages
English (en)
Other versions
RU2736245C2 (ru
RU2018127191A3 (ru
Inventor
Лоренцо БЕЛЛОРИНИ
Лука НОЧЕЛЛИ
Тициано ФОССАТИ
Original Assignee
Альтергон С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альтергон С.А. filed Critical Альтергон С.А.
Publication of RU2018127191A publication Critical patent/RU2018127191A/ru
Publication of RU2018127191A3 publication Critical patent/RU2018127191A3/ru
Application granted granted Critical
Publication of RU2736245C2 publication Critical patent/RU2736245C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (19)

1. Композит, состоящий из: гидроксипропил-β-циклодекстрина (HPβCD), сукралозы, активного фармацевтического ингредиента (АФИ), необязательно водного носителя, и при этом указанный АФИ находится в комплексе с указанным HPβCD, где композит имеет молярное соотношение НРβCD:сукралоза от 1:0,05 до 1:0,8 и АФИ представляет собой стероид.
2. Композит по п. 1, имеющий молярное соотношение АФИ:НРβСБ от 1:1 до 1:4.
3. Композит по любому из пп. 1, 2, имеющий молярное соотношение АФИ:сукралоза от 1:0,05 до 1:2.
4. Композит по любому из пп. 1-3, в котором указанный стероид выбран из тестостерона, прогестерона и их производных.
5. Способ получения композита по любому из пп. 1-4, включающий образование комплекса АФИ в HPβCD в присутствии сукралозы.
6. Способ по п. 5, включающий следующие стадии:
a. растворение HPβCD (или сукралозы) в водном носителе.
b. растворение сукралозы (или HPβCD) в растворе, полученном на стадии а.
c. добавление АФИ в раствор, полученный на стадии b.
d. необязательно удаление водного носителя.
7. Способ по любому из пп. 5-6, в котором на стадии d. водный носитель удаляют лиофильной сушкой или распылительной сушкой.
8. Способ по любому из пп. 5-7, в котором продукт, полученный на стадии (d) представляет собой аморфное твердое вещество.
9. Композит, полученный способом по любому из пп. 5-8.
10. Фармацевтическая композиция, содержащая композит по любому из пп. 1-4, 9.
11. Фармацевтическая композиция по п. 10, походящая для оромукозального введения.
12. Фармацевтическая композиция по любому из пп. 10, 11, выбранная из: порошка, гранулята, таблетки, минитаблетки, пилюли, геля, пленки.
13. Композит или композиция по любому из пп. 1-4, 9-12 для применения в способе лечения, характеризующемся оромукозальным введением.
14. Композит или композиция для применения по п. 13, где указанный АФИ представляет собой стероидный гормон, и указанное лечение направлено на заболевание, характеризующееся снижением продуцирования указанного гормона.
15. Композит или композиция для применения по п. 14, где указанный АФИ выбран из тестостерона или прогестерона.
RU2018127191A 2016-02-24 2017-02-24 Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы RU2736245C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITUB2016A001027A ITUB20161027A1 (it) 2016-02-24 2016-02-24 Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
IT102016000019030 2016-02-24
PCT/EP2017/054274 WO2017144636A1 (en) 2016-02-24 2017-02-24 High bioavailability oromucosal pharmaceutical preparations based on cyclodextrin and sucralose

Publications (3)

Publication Number Publication Date
RU2018127191A true RU2018127191A (ru) 2020-03-24
RU2018127191A3 RU2018127191A3 (ru) 2020-05-27
RU2736245C2 RU2736245C2 (ru) 2020-11-12

Family

ID=56116500

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127191A RU2736245C2 (ru) 2016-02-24 2017-02-24 Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы

Country Status (7)

Country Link
US (1) US20190021986A1 (ru)
EP (1) EP3419671B1 (ru)
CN (1) CN108778342B (ru)
CA (1) CA3013530A1 (ru)
IT (1) ITUB20161027A1 (ru)
RU (1) RU2736245C2 (ru)
WO (1) WO2017144636A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223393A1 (en) * 2019-04-30 2020-11-05 Taka Usa, Inc. METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC β-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF
JP2023526098A (ja) * 2020-05-18 2023-06-20 オレクソ・アクチエボラゲット 薬物送達のための新しい医薬組成物
WO2022181569A1 (ja) * 2021-02-24 2022-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 口腔内崩壊性組成物、カプセル剤、フィルムコーティング錠、フィルム製剤及び口腔内崩壊性の向上方法
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
CN116869927B (zh) * 2023-09-06 2023-11-10 中国医学科学院北京协和医院 一种用于治疗嗜酸性食管炎的食道温敏凝胶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4971797A (en) * 1988-12-22 1990-11-20 Warner-Lambert Company Stabilized sucralose complex
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US20060120967A1 (en) * 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
ITMI20071971A1 (it) * 2007-10-10 2009-04-11 Altergon Sa Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
CN101559077A (zh) * 2009-04-16 2009-10-21 官培龙 一种口腔炎症性疾病止痛用含漱液
US9173860B2 (en) * 2009-11-04 2015-11-03 Susan Park Perrine S isomers of α-methyl hydrocinnamic acid for the treatment of blood disorders
HK1161509A2 (en) * 2010-06-04 2012-07-27 Comprehensive Drug Entpr Ltd Oral meclizine aqueous formulations with taste flavoring agent
GB2482868A (en) 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
CN103610659B (zh) * 2013-12-06 2016-01-20 湖南中南大学湘雅口腔医院 一种大蒜素药物组合物及其制备方法

Also Published As

Publication number Publication date
US20190021986A1 (en) 2019-01-24
EP3419671A1 (en) 2019-01-02
CN108778342A (zh) 2018-11-09
ITUB20161027A1 (it) 2017-08-24
WO2017144636A1 (en) 2017-08-31
RU2736245C2 (ru) 2020-11-12
CA3013530A1 (en) 2017-08-31
RU2018127191A3 (ru) 2020-05-27
EP3419671B1 (en) 2021-02-17
CN108778342B (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
RU2018127191A (ru) Оромукозальные фармацевтические препараты с высокой биодоступностью на основе циклодекстрина и сукралозы
Celebioglu et al. Fast dissolving oral drug delivery system based on electrospun nanofibrous webs of cyclodextrin/ibuprofen inclusion complex nanofibers
Bandi et al. Preparation of budesonide–and indomethacin–hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process
Alshehri et al. Dissolution and bioavailability improvement of bioactive apigenin using solid dispersions prepared by different techniques
FI3258919T4 (fi) Nasaalinen jauheformulaatio hypoglykemian hoitoon
MY178082A (en) Solid pharmaceutical compositions and processes for their production
AR037642A1 (es) Preformulacion farmaceutica para tabletado, y procedimiento para su preparacion
NZ631100A (en) Soft chewable pharmaceutical products
WO2019025863A3 (en) MEDICAMENT COMPOUND AND METHODS OF PURIFICATION
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
Vadlamudi et al. Significance of excipients to enhance the bioavailability of poorly water-soluble drugs in oral solid dosage forms: A Review
AR093012A1 (es) Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion
EP2895147B1 (en) Rapidly dissolving pharmaceutical composition
NZ602441A (en) A fast dissolving pharmaceutical composition
WO2016040814A3 (en) Disulfide polymers and methods of use
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
AR055953A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
Ruz et al. Characterization and molecular modeling of the inclusion complexes of 2-(2-nitrovinyl) furan (G-0) with cyclodextrines
WO2012164575A3 (en) Amorphous ritonavir co-precipitated
JP2016501225A5 (ru)
RU2016106384A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
Espinosa Silva et al. Purification of the antichagasic benznidazole from the commercial preparation Rochegan®: characterization of inclusion complexes with β-cyclodextrin
WO2014181368A8 (en) Aqueous ophthalmic formulations based on azithromycin
FI3258920T3 (fi) Juomavesilääkkeenä käytettäväksi soveltuva kiinteä farmaseuttinen annosmuoto